Mechanism of cytotoxicity and resistance of ar senic tr ioxide in cancer cells
Date Issued
1999-07-31
Date
1999-07-31
Author(s)
陳耀昌
DOI
882314B002064
Abstract
Arsenic trioxide is a novel anticancer
agent, which has been found to induce
remission in acute promyelocytic leukemic
patients following daily intravenous
administration. The therapeutic value of
arsenic trioxide in other cancers is still
largely unknown. Our previous study showed
that bladder cancer, acute promyelocytic
leukemic and gastrointestinal cancer cells
were the most sensitive to arsenic trioxide.
Cellular glutathione system plays an
important role in arsenic detoxification in
mammalian cells. Cancer cells that were
intrinsically sensitive to arsenic trioxide
contained lower levels of glutathione
whereas resistant cancer cells contained
higher levels of glutathione. On the other
hand, there was no association of
glutathione-s-transferase-pi or multidrug
resistance-associated protein 1 levels with
arsenic sensitivity in these cancer cells. In the
present study we have shown that multidrug
resistant cancer cells that were cross-resistant
to arsenic contained higher levels of
glutathione or multidrug-resistance
associated protein 1 than their drug-sensitive
parental cells. Cancer cells become more
sensitive to arsenic after depletion of cellular
glutathione with L-buthionine sulfoximine.
We concluded that cellular glutathione level
is the most important determinant of arsenic
sensitivity in cancer cells. Cellular
glutathione level and its modulation by
buthionine sulfoximine should be considered
in designing clinical trials using arsenic in
solid tumors.
Subjects
氧化砷
癌症治療
抗藥性
SDGs
Publisher
臺北市：國立臺灣大學醫學院檢驗醫學科
Type
journal article
File(s)![Thumbnail Image]()
Loading...
Name
882314B002064.pdf
Size
132.04 KB
Format
Adobe PDF
Checksum
(MD5):8f7d1f2040f47a4d7a51e2c460c1cd6f